Apramycin - Juvabis Therapeutics
Alternative Names: EBL-1003Latest Information Update: 09 Aug 2024
Price :
$50 *
At a glance
- Originator Aventis
- Developer Juvabis Therapeutics; University of Zurich
- Class Aminoglycosides; Antibacterials; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gram-negative infections
- Preclinical Gram-positive infections
Most Recent Events
- 09 Aug 2024 Apramycin is still in phase I trials for phase-I development in Gram-negative-infections (In volunteers) in Germany (Juvabis pipeline, August 2024)
- 13 Jun 2024 Preclinical trials in Gram-positive infections in Switzerland (unspecified route) prior to June 2024
- 13 Jun 2024 Antimicrobial data from a preclinical study in Gram-positive infections presented at the ASM Microbe 2024 (ASMM-2024)